ANI Pharmaceuticals

pharma

Baudette, MN · ANIP · Public

ANI Pharmaceuticals is undergoing a strategic shift toward rare disease specialization, with Cortrophin Gel emerging as a defining growth driver for 2026 and beyond. The company is expanding Cortrophin's market reach into acute gout treatment with a dedicated 90-person sales force while maintaining its core generic and specialty pharmaceutical manufacturing operations.

ANI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, concentrating on the development, production, and commercialization of both proprietary (branded) and unbranded (generic) prescription medications across the United States and Canada. The company's primary focus areas include manufacturing controlled substances, treatments for oncology, hormones and steroids, injectable drugs, and various other pharmaceutical preparations. Its robust manufacturing capabilities encompass a range of dosage forms, such as oral solid products, semi-solids, liquid formulations, and topical agents, as well as highly potent compounds. Furthermore, ANI Pharmaceuticals provides contract development and manufacturing services to other pharmaceutical enterprises. The company distributes its products through a diverse network, which includes retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, and group purchasing organizations. Incorporated in 2001, its corporate headquarters are situated in Baudette, Minnesota.

Employees

897

Mfg Plants

All Facilities

Activity

7/10

Type

Public